Contributions
Abstract: EP1650
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Background: Medication adherence to is the extent to which a patient acts in accordance with the prescribed interval and dose. Little is known about the course of adherence to Disease Modifying Treatment (DMT) and its predictors in MS.
Methods:
Participants were PwMS (relapsing-remitting) treated at Carmel MS Center in Haifa, Israel: 171 at baseline (T1) and 6 months (T2) and 126 at 12 months (T3).
Design - prospective survey at three time points combined with retrospective review of health records and medication claims.
Measures - predictors were habit, medication beliefs, illness perceptions, physical disability, emotional factors and demographic characteristics. Outcome was adherence as assessed by three indicators: medication withdrawal records and two patient-reported measures - Probabilistic Medication Adherence Scale (ProMAS) and MS-TEQ. Adherence was defined as either => 80% medication claims per regiment, or => 80% self-reported medication use by MS-TEQ or being at medium-high and high categories of ProMAS.
Results: Adherence rates were: 62%, 62% 63.5% at Time1, time2 and Time3, respectively. Adherence by modalities was 57.5% vs. 65.9% for injections and oral, respectively at time1, 48.5% vs. 72.9% for injections and oral, respectively at time2 and 59.6% vs. 66.7% for injections and oral, respectively at time3. The difference was significant only at time 2 (χ 2(1)=9.57, p=0.002) . Time2 adherence was predicted by medication perceptions of over-treatment and harm at time1 (t(150)=2.37, p=0.019 and t(150)=2.39, p=0.018 respectively) time3 adherence was predicted by habit strength at time2 (χ 2(1)=3.77, p=0.05). Emotional states, disability and demographic characteristics were not predictive of adherence at the 3 time points (one exception: gender at time1).
Conclusions: As PwMS gain more experience with their medication, the predictors for adherence change from general perceptions to the strength of habit with the particular medication. Future interventions in medication adherence should take into consideration the different perceptions at different treatment stages.
Disclosure: The study is supported by research support from Biogen, Merck-Serono and Novartis
Abstract: EP1650
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Background: Medication adherence to is the extent to which a patient acts in accordance with the prescribed interval and dose. Little is known about the course of adherence to Disease Modifying Treatment (DMT) and its predictors in MS.
Methods:
Participants were PwMS (relapsing-remitting) treated at Carmel MS Center in Haifa, Israel: 171 at baseline (T1) and 6 months (T2) and 126 at 12 months (T3).
Design - prospective survey at three time points combined with retrospective review of health records and medication claims.
Measures - predictors were habit, medication beliefs, illness perceptions, physical disability, emotional factors and demographic characteristics. Outcome was adherence as assessed by three indicators: medication withdrawal records and two patient-reported measures - Probabilistic Medication Adherence Scale (ProMAS) and MS-TEQ. Adherence was defined as either => 80% medication claims per regiment, or => 80% self-reported medication use by MS-TEQ or being at medium-high and high categories of ProMAS.
Results: Adherence rates were: 62%, 62% 63.5% at Time1, time2 and Time3, respectively. Adherence by modalities was 57.5% vs. 65.9% for injections and oral, respectively at time1, 48.5% vs. 72.9% for injections and oral, respectively at time2 and 59.6% vs. 66.7% for injections and oral, respectively at time3. The difference was significant only at time 2 (χ 2(1)=9.57, p=0.002) . Time2 adherence was predicted by medication perceptions of over-treatment and harm at time1 (t(150)=2.37, p=0.019 and t(150)=2.39, p=0.018 respectively) time3 adherence was predicted by habit strength at time2 (χ 2(1)=3.77, p=0.05). Emotional states, disability and demographic characteristics were not predictive of adherence at the 3 time points (one exception: gender at time1).
Conclusions: As PwMS gain more experience with their medication, the predictors for adherence change from general perceptions to the strength of habit with the particular medication. Future interventions in medication adherence should take into consideration the different perceptions at different treatment stages.
Disclosure: The study is supported by research support from Biogen, Merck-Serono and Novartis